November 21, 2019 Trial Shows Switch from Etanercept Biologic to Biosimilar Maintains Clinical Outcomes A new study shows that the clinical status of patients who have either rheumatoid arthritis or axial spondyloarthritis, can be successfully maintained when switching from the biologic originator etanercept to a biosimilar called SB4. Learn more   High Rates of Inappropriate Opioid Use Found in SLE A large proportion of patients with systemic lupus erythematosus (SLE) have been inappropriately prescribed opioids, researchers reported recently in the Morbidity and Mortality Weekly Report. Learn more   RELATED Here's why there are no new treatments for lupus Rheumatoid Arthritis Pain Persists Despite TNF Inhibitor Use Despite Warnings, Opioid Prescriptions Still Widespread In Osteoarthritis Biosimilars Report: 52-Week Long Study Results Support Etanercept Biosimilar